港股午评|恒生指数早盘跌0.29% 生物医药板块拖累指数

Market Overview - The Hang Seng Index fell by 0.29%, down 75 points, closing at 26,124 points, while the Hang Seng Tech Index decreased by 0.09%. The early trading volume in Hong Kong stocks reached HKD 176.3 billion [1]. Pharmaceutical Sector - The pharmaceutical sector experienced a significant decline, with multiple stocks opening down over 10%. Reports indicate that the Trump administration is considering restrictions on Chinese pharmaceuticals. Notable declines include Hansoh Pharmaceutical down 9%, CSPC Pharmaceutical down 7.5%, and Innovent Biologics down 3.3% [1]. Metals Sector - The non-ferrous metals sector saw gains, driven by a quarter-on-quarter increase in basic metal performance. Companies such as China Hongqiao rose by 3.97%, Jiangxi Copper by 3.2%, and China Aluminum by 3.64% [1]. Semiconductor Industry - The semiconductor industry is expected to continue its "AI-driven + self-controlled" dual development trend in the second half of the year. Semiconductor stocks collectively rose, with Hua Hong Semiconductor and SMIC both increasing by over 5% [1]. Telecommunications - ZTE Corporation saw a rise of 7.62%, as the company accelerates its expansion from connectivity to computing power, with institutions optimistic about its stable performance [1]. Virtual Asset Trading - Yunfeng Financial surged over 18%, following a nearly 28% increase the previous day, after receiving approval to provide virtual asset trading services [2]. Fiber Optics - Longi Fiber Optics experienced a rise of over 14%, driven by increased demand for AI-driven data center interconnectivity, with institutions viewing the company as a core beneficiary [2]. Biotechnology - Rongchang Biopharmaceuticals increased by over 5%, as its drug Taitasip became the first biopharmaceutical to apply for listing in the field of Sjögren's syndrome globally [3]. Clinical Trials - Yaojie Ankang-B saw an increase of over 11%, with its market capitalization surpassing HKD 40 billion after receiving approval to conduct Phase II clinical trials for its drug Tienogitini [4]. Technology Sector - Huiju Technology rose over 10% after entering the Hong Kong Stock Connect list, with expectations of rapid growth in its MPO business over the coming years [5]. Strategic Partnerships - Charoen Pokphand International rose by 3% following a strategic partnership with Muyuan Group, as the company is a producer of the antibiotic goldmine under Charoen's umbrella [5]. Market Trends - Shenzhou Holdings increased by over 8%, driven by hot concepts and performance growth propelling its stock price [5].